Infliximab against severe COVID-19-induced cytokine storm syndrome with organ failure-a cautionary case series
- PMID: 32680535
- PMCID: PMC7366555
- DOI: 10.1186/s13054-020-03158-0
Infliximab against severe COVID-19-induced cytokine storm syndrome with organ failure-a cautionary case series
Conflict of interest statement
Outside of the study, AS has received consulting fees from AbbVie, Amgen, Celltrion, Janssen, MSD, Mundipharma, and Takeda; lecture fees and support for travel accommodation from AbbVie, Amgen, FalkFoundation, Janssen, MSD, and Takeda; and research funding from Abbvie and Celltrion.
Figures

Comment in
-
Infliximab can reduce mortality from 35 to 14% in critically ill patients with COVID-19: perhaps some potential confounders to consider.Crit Care. 2020 Oct 9;24(1):603. doi: 10.1186/s13054-020-03294-7. Crit Care. 2020. PMID: 33036639 Free PMC article. No abstract available.
References
-
- Brenner EJ, Ungaro RC, Colombel JF, Kappelman MD. IBD Database public data update https://covidibd.org/current-data/2020.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources